Palisade Bio (PALI) EBT Margin (2011 - 2023)

Palisade Bio's (PALI) quarterly EBT Margin came in at 15269.2% in Q1 2023, up 88.27% on a QoQ basis from 130216.12% in Q4 2020.

Palisade Bio (PALI) EBT Margin (2011 - 2023) Analysis & Trends

Palisade Bio (PALI) has 11 years of EBT Margin data on file, last reported at 15269.2% in Q1 2023.

On a quarterly basis, EBT Margin changed N/A year-over-year to 15269.2% in Q1 2023; TTM through Dec 2023 was 19497.6%, a N/A change from a year earlier, with the FY2023 full-year figure at 16808.8%, changed N/A from the prior year.
EBT Margin for Q1 2023 stood at 15269.2%, up from 130216.12% in the prior quarter.
Over the last five years, EBT Margin for PALI reached as high as 15269.2% in Q1 2023 and fell as low as 130216.12% in Q4 2020.
Historically, EBT Margin has averaged 70080.01% across 3 years, with a median of 75960.88% in 2020.
On a YoY basis, EBT Margin climbed as much as 5895662 bps in 2020 and fell as far as 5154577 bps in 2020.
Year by year, EBT Margin stood at 84976.44% in 2019, then slumped by 53 bps to 130216.12% in 2020, then soared by 88 bps to 15269.2% in 2023.
Per Business Quant data, the three most recent EBT Margin figures were 15269.2% in Q1 2023, 130216.12% in Q4 2020, and 73918.76% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	17.13%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	41.95%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.05%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	34.77%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Palisade Bio	985.76	-132.63 Mn	-	-

Download Data